Showing results (1701-1710 of 1,838) with videos related to
Sort By:
Pageof 184
Biology of Reproduction|April 11, 2018
Sox17 is essential for proper formation of the marginal zone of extraembryonic endoderm adjacent to a developing mouse placental diskHitomi Igarashi, Mami Uemura, Ryuji Hiramatsu, et al.Epilepsia Open|June 12, 2020
Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open-label Study 342 (FREEDOM Study)Takamichi Yamamoto, Sung Chul Lim, Hirotomo Ninomiya, et al.Epilepsia Open|April 13, 2023
Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medicationKazuyuki Fukushima, Hiroyuki Higashiyama, Yuji Kazuta, et al.Journal of Atherosclerosis and Thrombosis|September 5, 2014
Risk of hypercholesterolemia for cardiovascular disease and the population attributable fraction in a 24-year Japanese cohort studyDaisuke Sugiyama, Tomonori Okamura, Makoto Watanabe, et al.Current Biology : CB|March 6, 2021
Embryonic evidence uncovers convergent origins of laryngeal echolocation in batsTaro Nojiri, Laura A B Wilson, Camilo López-Aguirre, et al.Scientific Reports|May 6, 2021
Functionally confirmed compound heterozygous ADAM17 missense loss-of-function variants cause neonatal inflammatory skin and bowel disease 1Issei Imoto, Masako Saito, Kenichi Suga, et al.Kidney International|December 12, 2001
Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cellsY Uchiyama-Tanaka, H Matsubara, Y Nozawa, et al.Gastroenterology|March 4, 2003
Liver regeneration in heparin-binding EGF-like growth factor transgenic mice after partial hepatectomyShinichi Kiso, Sumio Kawata, Shinji Tamura, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLCRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Journal for Immunotherapy of Cancer|June 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancerRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.Pageof 184